) to the formation of the predisposition to juvenile idiopathic arthritis (JIA) and its
clinical variants. Material
Gareev, I,
Gileva, Y,
Dzidzaria, A,
Beylerli, O,
Pavlov, V,
Agaverdiev, M,
Mazorov, B,
Biganyakov, I,
Vardikyan, A,
Jin, M,
Ahmad, A (2021) of
clinical trials dedicated to oncourology have begun, using lncRNA as new biomarkers or treatments